Carvedilol versus traditional, non‐selective beta‐blockers for adults with cirrhosis and gastroesophageal varices

Background Non‐selective beta‐blockers are recommended for the prevention of bleeding in people with cirrhosis, portal hypertension and gastroesophageal varices. Carvedilol is a non‐selective beta‐blocker with additional intrinsic alpha1‐blocking effects, which may be superior to traditional, non‐selective beta‐blockers in reducing portal pressure and, therefore, in reducing the risk of upper gastrointestinal bleeding.